<DOC>
	<DOCNO>NCT00253513</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , treosulfan fludarabine , work different way stop growth cancer cell , either kill cell stop divide . Giving treosulfan fludarabine together donor bone marrow transplant peripheral stem cell transplant may effective treatment acute myeloid leukemia , acute lymphoblastic leukemia , myelodysplastic syndrome . PURPOSE : This phase II trial study give treosulfan together fludarabine see well work treat patient undergo donor stem cell transplant acute myeloid leukemia , acute lymphoblastic leukemia , myelodysplastic syndrome .</brief_summary>
	<brief_title>Treosulfan Fludarabine Treating Younger Patients Who Are Undergoing Donor Stem Cell Transplant Acute Myeloid Leukemia , Acute Lymphoblastic Leukemia , Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : Primary Phase - Determine best dose treosulfan administer fludarabine reduced-intensity condition regimen follow allogeneic hematopoietic stem cell transplantation , term incidence severe fatal toxicity major organ system incidence graft failure , patient acute myeloid leukemia , lymphoblastic leukemia , myelodysplastic syndrome . Secondary Phase - Determine safety regimen , term incidence grade II-IV acute chronic graft-versus-host disease , patient . - Determine , preliminarily , efficacy regimen , term incidence relapse , overall disease-free survival , donor chimerism day 28 100 , incidence 200-day 1-year nonrelapse mortality , patient . - Determine pharmacokinetic pharmacodynamic profile treosulfan patient treat regimen . OUTLINE : This multicenter , dose-finding study treosulfan . - Reduced-intensity conditioning : Patients receive treosulfan IV 2 hour day -6 -4 fludarabine IV 30 minute day -6 -2 . Cohorts 5-10 patient receive escalating/de-escalating dos treosulfan best dose determine among 3 pre-selected dos . The best dose define dose precede 4 10 patient experience dose-limiting toxicity . - Allogeneic hematopoietic cell transplantation ( AHCT ) : Patients undergo allogeneic bone marrow peripheral blood stem cell transplantation day 0 . All male patient acute lymphoblastic leukemia OR male patient acute myeloid leukemia prior current testicular involvement receive external-beam radiotherapy testicle AHCT . After completion study treatment , patent follow periodically . PROJECTED ACCRUAL : A total 60 patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Treosulfan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute myeloid leukemia , lymphoblastic leukemia , myelodysplastic syndrome Any phase allow , include follow : Disease remission Relapsed primary refractory disease No CNS leukemic involvement clear prior intrathecal chemotherapy and/or cranial radiotherapy Planning undergo unmanipulated allogeneic bone marrow peripheral blood stem cell transplantation Filgrastim ( GCSF ) mobilization bone marrow stem cell allow Donor available , meet 1 follow criterion : HLAidentical relate donor HLAA , B , C , DRB1 , DQB1 match unrelated donor highresolution DNA type A single allele mismatch allow PATIENT CHARACTERISTICS : Performance status Karnofsky 70100 % OR Lansky 70100 % Life expectancy Not specify Hematopoietic Not specify Hepatic Bilirubin ≤ 2 time upper limit normal ( ULN ) AST ≤ 2 time ULN No evidence synthetic dysfunction No severe cirrhosis No active infectious hepatitis Renal Creatinine clearance ≥ 50 % Creatinine ≤ 2 time ULN Dialysis independent Cardiovascular No cardiac insufficiency require treatment No symptomatic coronary artery disease Ejection fraction ≥ 35 % ( patient history cardiac disease anthracycline exposure ) Pulmonary PO_2 ≥ 70 mm Hg AND DLCO ≥ 70 % predict OR PO_2 ≥ 80 mm Hg AND DLCO ≥ 60 % predict Not require supplementary continuous oxygen Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No disease would severely limit life expectancy No HIV positivity No active infection require deferral conditioning No known hypersensitivity study drug PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics No prior allogeneic bone marrow stem cell transplantation No concurrent umbilical cord blood autologous transplantation Chemotherapy See Disease Characteristics Radiotherapy See Disease Characteristics Other More 4 week since prior experimental drug Concurrent enrollment another protocol graftversushost disease prophylaxis allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>